Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Amgen

Status and phase: Terminated; Phase 4

Conditions: Psoriasis

Treatments: Drug: Etanercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT01543204

20101145

Details and patient eligibility

About

This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.

Enrollment: 64 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate to severe plaque psoriasis
• Loss of satisfactory response to adalimumab
• Currently receiving or recently discontinued treatment with adalimumab

Exclusion criteria

• Active skin conditions that would interfere with evaluations of the effect of investigational product on psoriasis
• Serious medical conditions

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

64 participants in 1 patient group

Etanercept 50 mg

Experimental group

Description:

Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.

Treatment:

Drug: Etanercept